Agmatine: An endogenous ligand of imidazoline receptors

Eksperimental'naya i Klinicheskaya Farmakologiya

Volumn 66, Issue 5, 2003, Pages 69-73

  Kozaeva, L P ^a   Korobov, N V ^a  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE RECEPTOR; LIGAND; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DRUG RECEPTOR; IMIDAZOLINE RECEPTORS;

ADRENERGIC SYSTEM; ANIMAL CELL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; MEDULLA OBLONGATA; NERVE CELL; NONHUMAN; RAT; ANIMAL; BRAIN; HUMAN; METABOLISM; REVIEW;

AGMATINE; ANIMALS; BRAIN; HUMANS; LIGANDS; NEUROTRANSMITTER AGENTS; RECEPTORS, DRUG;

EID: 1542645820     PISSN: 08692092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. K. Abe, Y. Abe, and H. Saito, Brain Res., 872, 141-148 (2000).
2. F. Aricioglu-Kertal and I. T. Uzbay, Life Sci., 61, 1775-1881 (1998).
3. F. Aricioglu-Kertal and S. Reguanthan, Life Sci., 71, 1695-1701 (2002).
4. N. Anis, S. Sherby, R. Jr Goodnow, et al., J. Pharmacol. Exp. Ther., 254, 764-773 (1990).
5. M. A. Boronat, G. Olmos and J. Garcia-Sevilla, Ann. N. Y. Acad. Sci., 881, 359-363 (1999).
6. P. Bousquet, J. Feldman, and J. Schwarz, J. Pharmacol. Exp. Ther., 230, 232-236 (1984).
7. G. Bricca, H. Greney, J. Zhang, M. Dontenwill, et al., Eur. J. Pharmacol., 266, 25-33 (1994).
8. T. C. Chu, R. R. Socci, M. J. Ogidigbenet al., Ocul. Pharmacol. Ther., 13, 489-497 (1997).
9. R. M. Eglen, A. L. Hudson, D. A. Kendall, et al., Trends Pharmacol. Sci., 19, 381-390 (1998).
10. P. Ernsberger, M. P. Meeley, J. J. Mann and D. J. Reis, Eur. J Pharmacol., 134, 1-13 (1987).
11. C. A. Fairbanks, K. L. Schreiber, K. L. Brewer, C. G. Yu, et al., Proc. Natl. Acad. Sci. USA, 97, 10584-10589 (2000).
12. Y. Feng, A. E. Halaris, and J. E. Piletz, J. Chromatogr., 691, 277-286 (1997).
13. E. Galea, S. Regunathan, V. Eliopoulos, et al., Biochem. J., 316, 247-256 (1996).
14. Y. Gao, B. Gumusel, G. Koveset, et al., Life Sci., 57(8), 83-89 (1995).
15. J. A. Garcia-Sevilla, P. V. Escriba, M. Sastre, et al., J. Arch. Gen. Psychiatry, 53(9), 803-813 (1996).
16. J. A. Garcia-Sevilla, P. V. Escriba, C. Walzer, et al., Neurosci. Lett., 247(2-3), 95-113 (1998).
17. C. Gargalidis-Moudanos, N. Pizzinat, F. Javoy-Agid, et al., Neurochem. Int., 30(1), 31-37 (1997).
18. C. Gonzalez, S. Regunathan, D. J. Reis, and C. Estrada, Br. J. Pharmacol, 119, 677-684 (1996).
19. S. Greenberg, J. George, Y. Wollman, et al., J. Cardiovac. Pharmacol., 6, 37-45 (2001).
20. R. K. Iyer, H. K. Rim, R. W. Tsoa, W. W. Grody at al., Mol. Genet. Metab., 75, 209-218 (2002).
21. S. Ishizuka, R. Cunard, S. Poucell-Hatton, L. Wead, et al., J. Am. Soc. Nephrol., 11, 2256-2264 (2000).
22. T. D. Jonson, TIPS, 17, 22-27 (1996).
23. Y. Kolesnikov, S. Jain, and G. W. Pasternak, Eur. J. Phermacol., 296, 17-22 (1996).
24. A. Kuzirian E. Meyhofer, L. Hill, J. T. Neary, and D. L. Alkon, J. Neurocytol., 15, 629-643 (1986).
25. R. H. Loring, Br. J. Pharmacol, 99, 207-211 (1990).
26. G. Li, S. Regunathan, C. J. Barrow, J. Eshraghi, et al., Science, 263, 966-969 (1994).
27. G. Li, S. Regunathan and D. J. Reis, Ann. N. Y. Acad. Sci., 763, 325-329 (1995).
28. Q. Li, Z. Z. Fan, Y. H. Wang, and R. R. He, Sheng Li Xue Bao, 53(6), 451-455 (2001).
29. Q. Li and R. R. He, Sheng Li Xue Bao, 53(2), 133-136 (2001).
30. I. Martin-Gomez, J. Ruiz, L. F. Collado, et al., Neurorepot, 7(8), 1393-1399 (1996).
31. J. Molderings, K. Schmidt, H. Bonisch, and M. Gothert, Arch. Pharmacol., 354, 245-252 (1996).
32. GJ. Molderings, Drugs Future, 22, 757-772 (1997).
33. GJ. Molderings, M. Burian, S. Menzel, K. Donecker, et al., Ann. N. Y. Acad. Sci., 881, 332-334 (1999).
34. G. J. Molderings, S. Menzel, M. Kathmann, et al., Br. J. Pharmacol., 130, 1706-1712 (2000).
35. G. J. Molderings, A. Heinen, S. Menzel and M. Gothert, Fund. Clin. Pharmacol., 16, 219-225 (2002).
36. N. G. Morgan, S. L. Chan, M. Mourtada, et al., Ann. N. Y. Acad. Sci., 881, 217-228 (1999).
37. K. Otake, D. A. Ruggiero, S. Regunathan, et al., Brain Res., 787, 1-14 (1998).
38. J. E. Piletz, D. N. Chikkala, and P. Ernsberger, J. Pharmacol. Exp. Ther., 272, 581-587 (1995).
39. D. Pinthong, I. K. Wright, C. Hanmer, et al., Naunyn-Schmidebergs Arch. Pharmacol., 351, 10-16 (1995).
40. D. Pinthong, J. F. Hussain, D. A. Kendall, and V. G. Wilson, Br. J. Pharmacol., 115, 689-695 (1995).
41. X. M. Qin and R. R. He, Acta. Pharmocol. Sin., 22(3), 264-268 (2001).
42. M. Quik, Brain Res., 325, 79-88 (1985).
43. W. Raasch, S. Regunathan, G. Li, and D. J. Reis, Life Sci., 56, 2319-2330 (1995).
44. S. Reguanthan, D. L. Feinstein, W. Raasch, and D. J. Reis, Neurorepot, 6(14), 1897-1900 (1995).
45. S. Reguanthan, C. Youngson, W. Raasch, et al., J. Pharmacol. Exp. Ther., 276, 1272-1282 (1996).
46. D. J. Reis and S. Reguanthan, Adv. Pharmacol., 42, 645-649 (1998).
47. D. J. Reis, X. Yang, and T. A. Milner, Neurosci. Lett., 250, 185-188 (1998).
48. D. J. Reis and S. Regunathan, Ann. N. Y. Acad. Sci., 881, 65-80 (1999).
49. M. Sastre, S. Regunathan, and D. J. Reis, J. Neurochem., 67, 1761-1765 (1996).
50. M. Sastre, S. Regunathan, and D. J. Reis, J. Neurochem., 69, 2421-2426 (1997).
51. U. Schafer, W. Raasch, F. Qadri, et al., Ann. N. Y. Acad. Sci., 881, 97-101 (1999).
52. M. K. Sun, S. Regunathan, and D. J. Reis, Clin. Exp. Hypertens., 17, 115-128 (1995).
53. B. Szabo, R. Urban, N. Limberger, and K. Starke, Naunyn-Schmidebergs Arch. Pharmacol., 351, 268-273 (1995).
54. W. C. Tabor and H. Tabor, Ann. Rev. Biochem., 53, 749-790 (1984).
55. I. T. Uzbay, O. Yesilyurt, T. Celik, H. Ergun et al, Behav. Brain Res., 107, 153-159 (2000).
56. X. Yang and D. J. Reis, J. Pharmacol. Exp. Ther., 228, 544-549 (1999).
57. O. Yesilyurt and I. T. Uzbay, Neuropsychopharmacol., 25, 98-103 (2001).
58. A. D. Zomkowski, L. Hammes, J. Lin, et al., Neuroreport, 13, 387-391 (2002).